Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMW4M97)

Drug Name
Clevidipine butyrate Drug Info
Synonyms
Clevidipine; Cleviprex; 167221-71-8; Clevelox; rac-Clevidipine; H 324/38; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dime thyl-3,5-pyridinedicarboxylate; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Cleviprex (TN); 3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; METHYL 5-{[(BUTANOYLOXY)METHOXY]CARBONYL}-4-(2,3-DICHLOROPHENYL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE-3
Cross-matching ID
PubChem CID
153994
ChEBI ID
CHEMBL1237132
CAS Number
CAS 167221-71-8
TTD Drug ID
D09ELP
INTEDE Drug ID
DR0339
ACDINA Drug ID
D00953

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
NF-kappa B signaling pathway 2.19 0.00e+0 90/104 (86.54%) CXCL2;CXCL3;CXCL1;...
IL-17 signaling pathway 2.18 0.00e+0 84/94 (89.36%) CXCL2;S100A7;DEFB4A;...
Rheumatoid arthritis 2.05 0.00e+0 78/93 (83.87%) CXCL2;CXCL3;CXCL1;...
Viral protein interaction with cytokine and cytokine re... 1.99 6.00e-3 84/100 (84%) CXCL2;CXCL3;CXCL1;...
TNF signaling pathway 1.98 4.80e-3 103/112 (91.96%) CXCL2;CXCL3;CXCL1;...
Asthma 1.90 8.00e-3 25/31 (80.65%) CD40;FCER1A;HLA-DOB;...
Chemokine signaling pathway 1.86 1.54e-2 163/192 (84.9%) CXCL2;CXCL3;CXCL1;...
Epithelial cell signaling in Helicobacter pylori infect... 1.85 1.65e-2 62/70 (88.57%) CXCL2;CXCL3;CXCL1;...
B cell receptor signaling pathway 1.73 4.80e-2 71/81 (87.65%) FOS;LYN;AKT3;...
Linoleic acid metabolism -1.68 4.39e-2 21/29 (72.41%) CYP1A2;CYP3A4;PLAAT3;...
Biosynthesis of unsaturated fatty acids -1.68 4.75e-2 21/27 (77.78%) FADS1;FADS2;HACD2;...
Fat digestion and absorption -1.70 4.41e-2 35/43 (81.4%) NPC1L1;ABCA1;APOA4;...
Ferroptosis -1.77 2.24e-2 36/41 (87.8%) SLC3A2;GCLC;TP53;...
Arginine biosynthesis -1.77 2.69e-2 17/22 (77.27%) GLS;CPS1;ASS1
alpha-Linolenic acid metabolism -1.81 2.77e-2 17/25 (68%) ACOX1;PLAAT3;PLA2G2A;...
beta-Alanine metabolism -1.89 1.32e-2 25/30 (83.33%) ALDH1B1;ACADS;ECHS1;...
Valine, leucine and isoleucine degradation -1.90 1.58e-2 42/48 (87.5%) ECHS1;EHHADH;ALDH3A2;...
Propanoate metabolism -1.96 1.58e-2 30/34 (88.24%) ECHDC1;ACADS;LDHA;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 3.33uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H